Centro Médico Maffei - CABA, Buenos Aires
Somos un centro médico que posee una unidad dedicada únicamente a la Investigación Clínica desde hace 20 años. Nuestro personal es estable y bien entrenado anualmente en GPC. Nuestros archivos son dedicados a cada sponsor en forma exclusiva. Nuestro es droguero de acceso restringido, adecuadamente. El centro tiene acceso a internet de alta velocidad propia, base de datos y procedimientos internos informatizados. Contamos con siete consultorios bien equipados y una sala de monitoreo amplia para más de un monitor. Dirigido por la Dra. Laura Maffei.Av. Cerviño 3375, CABA, Buenos Aires
Websitehttps://www.maffei.com.ar/
Select an option
I am a doctor
I am a sponsor
Specializations
Gastroparesia diabética
Taquicardia supraventricular paroxística
Diabetes
Our team
Medical staff
José Manuel Crespo
Leila Santangelo
Katja Deus
Sonia Angelica Sassone
Laura Elena Maffei
María Alejandra Smuclir Quevedo
Emilio Alaguibe
Maria Jimena Coronel
Open studies
Diabetes
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity - Eli Lilly and CompanySee more
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) - Eli Lilly and CompanySee more
Lupus
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus - TOPAZ-2 - BiogenSee more
A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus - GALACELA - Galapagos NVSee more
Obesity
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity - Eli Lilly and CompanySee more
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) - TRIUMPH-OUTCOMES - Eli Lilly and CompanySee more
Alzheimer disease
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease - PROGRESS-AD - GlaxoSmithKlineSee more
Cardiovascular disease
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
